cyrilzakka/clinical-trials huggingface dataset:
Compare the Analgesic Effect of Different Anesthesia and Postoperative Analgesic Methods in Uniportal VATS Lung Surgery

This is a single center, randomized, single blind study to compare the analgesic effect of different anesthesia and postoperative analgesic methods in uniportal VATS lung surgery.

Combining epidural with general anesthesia is regarded as the gold standard of general thoracic surgery. The uniportal VATS lung surgery have advantages of minimal invasive surgical incision, less postoperative pain, and so on. Whether general anesthesia can become an alternative method of combining epidural with general anesthesia in uniportal VATS lung surgery, investigators thus plan to make a comparison on intraoperative stress response, postoperative pain, immune function of patients，and hospital expenses.

Eligibility Criteria:
Inclusion Criteria:

* Patients elective uniportal VATS lung surgery;
* BMI 18-30 kg/m2.

Exclusion Criteria:

* Patient refuse;
* ASA≥3;
* Patients allergic to use anesthetics (propofol,rocuronium), patients with liver and/or kidney and/or mental dysfunction.
Study of Postoperative 3D-CRT/IMRT in Hepatocellular Carcinoma

Hepatectomy is difficult when the tumor is adjacent to the big vessels of the liver and some patients can not receive radical resection. Such patients have high risk of recurrence. Tumor resection and postoperative radiation is an option for such patients to achieve radical treatment and radiation may reduce local recurrence.

Patients with risk factors of recurrence receive postoperative radiotherapy using intensive modulated radiation therapy (IMRT) or three-dimensional conformal radiation therapy (3DCRT). The clinical target volume includes tumor bed. The dose will be 50-60Gy/25-30f. Overall survival, local-recurrence free survival, disease free survival and toxicity need be observed.

Eligibility Criteria:
Inclusion Criteria:

* written informed consent provided
* 18\~75 years old
* patients with histopathological proved hepatocellular carcinoma received hepatectomy and had at least one risk factor of recurrence
* without any lymph node or distant metastasis (any T N0M0)
* liver function: Child-Pugh A or B
* Performance status: Karnofsky (KPS)≥70 or world health organization(WHO) score 0,1
* life expectation\>6 months
* no dysfunction of major organs
* no prior radiotherapy
* negative for human immunodeficiency virus syndrome (HIV)
* Considerable to computed tomography(CT) simulation and 3D-CRT or IMRT

Exclusion Criteria:

* malignant tumors of other sits
* combining severe diseases, such as acute myocardial infarction(AMI), arrhythmias, infection
* surgery performed in other hospitals without details
* pregnant woman or woman need to breast feed or woman with positive chorionic gonadotrophin (HCG)
Endoscopic Ultrasound-guided Celiac Plexus Neurolysis in the Management of Pain in Abdominal Non-pancreatic Malignancies

Celiac plexus neurolysis (CPN) has been performed for nearly 100 years to alleviate the abdominal pain associated with pancreatic malignancy and other conditions, and is usually undertaken at a late stage in the disease process, when analgesic options have been largely exhausted or have led to significant and often unacceptable side effects. Until recently, CPN was most commonly performed under radiographic guidance; however, in the last 10 years, CPN has been routinely performed under endoscopic ultrasound (EUS) guidance. Several case series have demonstrated the efficacy and safety of this technique when used to treat the pain associated with pancreatic malignancy and/or chronic pancreatitis. However, the efficacy of EUS-guided CPN in the treatment of pain related to non-pancreatic malignancies has yet to be described. The goal of this study is to assess the efficacy of EUS-guided CPN in the management of pain in patients with abdominal non-pancreatic malignancies. Our hypothesis is that EUS-guided CPN will provide adequate pain relief in these patients.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of an unresectable, non-pancreatic malignancy, including gastric, small intestinal, or proximal colonic malignancies, as well as malignancies of the liver and bile ducts (based on above celiac plexus innervations)
* Pain directly related to the primary malignant process, as determined by the referring oncologist
* Pain determined to be refractory to standard medical therapy, or when the medical therapy is ineffective due to certain limitations (such as severe constipation), as determined by the referring oncologist
* Willingness to undergo EUS-guided CPN
* Age \> 18 years
* ECOG performance status of grades 0-3 \[7\]
* The patient will need to sign informed consent prior to inclusion in this study

Exclusion Criteria:

* Unable or unwilling to undergo an EUS-guided CPN
* Contraindication to anesthesia, as determine during the preoperative clearance process
* Refractory coagulopathy (INR \> 1.5) or thrombocytopenia (platelet count \< 50,000), or aspirin and/or clopidogrel use within 7 days of procedure
* Current pregnancy
* Prior celiac plexus block/neurolysis
* Allergy to local anesthetics
* ECOG performance status of grade 4 or higher
Study of In-line Pressure Using Various Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT1A)

The purpose is to characterize the in-line pressure profiles associated with several infusion technique factors during subcutaneous (SC) infusion of Lactated Ringer's solution, preceded by recombinant human hyaluronidase (hylenex). The safety and tolerability of hylenex-augmented SC infusion of Lactated Ringer's solution fluid is also being evaluated.


Eligibility Criteria:
Inclusion Criteria:

* Male or female, aged 18 to 60 years, inclusive.
* Body mass index 19.0 to 35.0 kg/m2
* Intact normal skin without potentially obscuring tattoos, pigmentation, or lesions on the upper back in the area intended for infusion
* Free from any clinically significant abnormality on the basis of medical/medication history or physical examination
* Vital signs and clinical laboratory parameters within normal range or, if outside normal range, deemed not clinically significant
* Negative urine drug and alcohol screens.

Exclusion Criteria:

* Upper back pathology that could interfere with study outcome.
* History of congestive heart failure, known coronary heart disease, active or recent pulmonary disease, or renal insufficiency.
* Rales on lung auscultation.
* Known allergy to hyaluronidase or any other ingredient in the formulation of hylenex recombinant
* Treatment with furosemide, benzodiazepines, or phenytoin.
* Pregnancy or breastfeeding.
* Exposure to any experimental drug within 30 days prior to study admission, or previous participation in this study.
* Any other reason which, in the investigator's opinion, would prevent the safe participation in the study.
Intervention With n3 LC-PUFA-supplemented Yogurt

The effective dosage of a n3-LC-PUFA intervention (with n3 LC-PUFA-enriched yoghurt) on the modulation of cardiovascular risk factors and inflammatory biomarkers were determined.

Fifty three mildly hypertriacylglycerolemic subjects (TAG ≥ 150 mg/dL (1.7 mmol/L)) participated on the placebo-controlled, double-blind, parallel designed study.

The subjects consumed placebo yoghurt (1), or n3 LC-PUFA-enriched yoghurt (0.8 g n3 LC-PUFA/d (2), 3 g n3 LC-PUFA/d (3)) for 10 weeks.

Blood samples were taken at the beginning and at the end of the period.

Parameters:

* Blood lipids (total cholesterol, HDL, LDL, triacylglycerols)
* Fatty acid distribution of plasma lipids (PL) and erythrocyte membranes (EM)
* Concentrations of eicosanoids (PGs, HETEs)
* Production of ex vivo stimulated cytokines by T cells
* SNPs in the CD36 genotype

Eligibility Criteria:
Inclusion Criteria:

* hypertriacylglycerolemic subjects (TAG: ≥ 150 mg/dl (1.7 mmol/l))

Exclusion Criteria:

* patients receiving blood-diluting and lipid-lowering medications or glucocorticoids
* patients suffering from gastrointestinal or metabolic diseases (e.g., diabetes mellitus, hyper- and hypothyroidism) and hypercholesteremic patients with familial previous impacts
* patients taking dietary supplements (e.g., fish oil capsules, vitamin E) or having either known allergies or foodstuff indigestibility
* further exclusion criteria: smoking, high sportive activity or daily alcohol intake
Speech Motor Learning and Retention (Aim 1)

The overall goal of this research is to test a new model of speech motor learning, whose central hypothesis is that learning and retention are associated with plasticity not only in motor areas of the brain but in auditory and somatosensory regions as well. The strategy for the proposed research is to identify individual brain areas that contribute causally to retention by disrupting their activity with transcranial magnetic stimulation (TMS). Investigators will also use functional magnetic resonance imaging (fMRI) which will enable identification of circuit-level activity which predicts either learning or retention of new movements, and hence test the specific contributions of candidate sensory and motor zones. In other studies, investigators will record sensory and motor evoked potentials over the course of learning to determine the temporal order in which individual sensory and cortical motor regions contribute. The goal here is to identify brain areas in which learning-related plasticity occurs first and which among these areas predict subsequent learning.

The focus of this registration is Aim 1. The work in Specific Aim 1 involves tests of speech motor memory retention following disruption of left hemisphere brain activity in either auditory, somatosensory or motor cortex or to a control site (hand area motor cortex right hemisphere). Continuous theta-burst stimulation (cTBS) is delivered following adaptation to altered auditory feedback to assess its effects on the retention of new learning. In the adaptation task, participants read Harvard Sentences aloud, which are presented on a computer monitor. Vocal output is altered in real-time and played back to participants through headphones. Tests of retention are conducted 24 hours later.

The Speech Motor Learning and Retention Master Protocol has uniqueID 2000037622.

Eligibility Criteria:
Inclusion Criteria:

* Fluent English speakers
* Right-handed
* Normal hearing
* No speech disorder or reading disability

Exclusion Criteria:

* Cardiac pacemaker
* Aneurysm clip
* Heart or Vascular clip
* Prosthetic valve
* Metal implants
* Metal in brain, skull, or spinal cord
* Implanted neurostimulator
* Medication infusion device
* Cochlear implant or tinnitus (ringing in ears)
* Personal and/or family history of epilepsy or other neurological disorders or history of head concussion
* Psychoactive medications
* Pregnancy
Asunercept in Patients With Severe COVID-19

This is an open-label, randomized, phase II study with the main objective to investigate the effectiveness and safety of an investigational drug (APG101; International Nonproprietary Name: asunercept) in patients with severe COVID-19 disease. The study aims to decrease overall and SARS-CoV-2 associated pneumonia mortality in patients with COVID-19 as well as to decrease the percentage of patients admitted to Intensive Care Unit (ICU), decrease the need to supply oxygen to patients, reduce the number of days patients are hospitalized in ICU and/or on the ward, decrease the number of days required to obtain a negative result in the PCR (Polymerase Chain Reaction, a laboratory technique that allows the amplification of small fragments of DNA to detect the presence of the virus) test for COVID-19 and decrease the levels of markers that indicate pneumonia.


Eligibility Criteria:
Inclusion Criteria:

* Laboratory confirmed infection with SARS-CoV-2 OR typical radiological signs of SARS-CoV-2 infection
* Hospitalisation due to COVID-19
* Informed Consent obtained, the patient understands and agrees to comply with the planned study procedures. If a potential patient is unconscious, the Patient Information Sheet with the Informed Consent Form can be signed by the legal representative, if he/she accompanies the patient. It can be signed by a Concilium consisting of doctors (2), investigator and an independent witness in case the legal representative is not available.
* ≥18 years of age
* Willingness to perform effective measures of contraception during the study.
* Signs of respiratory deterioration such as oxygen saturation ≤94% when breathing ambient air or \>3% drop in oxygen saturation in case of chronic obstructive lung disease OR need for oxygen supplementation to achieve satisfactory blood oxygen saturation (sPO2\>90% at room air) as well as the need for non-invasive ventilation, high-flow oxygen devices or mechanical ventilation or radiological or clinical signs of pneumonia.

Exclusion Criteria:

* Moribund, or estimated life expectancy \<1 month (e.g., terminal cancer, etc.)
* Patient does not qualify for intensive care, based on local triage criteria
* Pregnancy or breast feeding
* Severe liver dysfunction (e.g. ALT/AST \> 5 times upper limit of normal)
* Anticipated discharge from hospital within 48 hours
* Other potent anti-inflammatory treatment, e.g. TNF- blocking therapies
* Mechanical ventilation for \>48 hours
* Known active HIV or viral hepatitis infection
* Known active tuberculosis
* Known hereditary fructose intolerance
The Third Epidemiological Research of Refractory Wounds in China

This study is a cross-sectional survey in patients who underwent treatment of chronic cutaneous wounds from a nationally representative sample in our hospital from January 2018 to December 2018．

Chronic cutaneous wounds represent a major health care burden in China However, limited information exists regarding the epidemiologic changes associated with recent social and economic devdopment．We designed a cross-sectional survey in patients who underwent treatment of chronic cutaneous wounds from a nationally representative sample in our hospital from January 2018 to December 2018．

Eligibility Criteria:
Inclusion Criteria:

- Patients who underwent treatment of chronic cutaneous wounds in our hospital from 1/2018-12/2018．

Exclusion Criteria:

- No
Immunophenotyping in Metastatic Kidney Cancer Patients Receiving Ablative Therapy

This early phase I trial evaluates blood samples to see if patients undergoing standard of care treatment with either stereotactic body radiation therapy or percutaneous ablation (using radio waves to create heat to destroy the tumor), have an increase in serum immune markers in kidney cancer. Information gained from this study may help doctors make treatment decisions for patients with kidney cancer.

PRIMARY OBJECTIVES:

I. Compare pre- and post-treatment immune markers and peripheral blood mononuclear cell (PBMC) characteristics in metastatic renal cell carcinoma (RCC) patients overall.

II. Compare pre- and post-treatment immune markers and PBMC characteristics between patients being treated with stereotactic body radiation therapy (SBRT) versus percutaneous cryoablation (PCA) and are also undergoing immunotherapy.

III. Compare pre- and post-treatment immune markers and PBMC characteristics in patients being treated with either SBRT or PCA and not undergoing immunotherapy.

IV. Assess the impact of post-treatment immune markers and PBMC characteristics on distant disease progression in metastatic RCC patients overall.

OUTLINE:

Patients undergo blood sample collection at baseline prior to SBRT or PCA, then at 14 days, 3 and 6 months after SBRT or PCA.

Eligibility Criteria:
Inclusion Criteria:

* Histological diagnosis of primary RCC
* Histological or radiographic diagnosis of metastatic RCC
* Age \>= 18 years
* Eastern Cooperative Oncology Group (ECOG) performance status 0-3
* Feasible vascular access as determined by study staff
* Undergoing standard of care SBRT or PCA to RCC metastatic lesion(s)
* Provide written informed consent
* Willing to consent to research blood draws
* Willing to return to enrolling institution for follow-up

Exclusion Criteria:

* Prior local treatment of the index metastatic lesion
* Pregnant or nursing women
* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for study entry
* Patients receiving prophylactic steroids, defined as initiation of steroids within 1 week prior to local ablative therapy start, including the first day of local ablative therapy.

  * NOTE: Patients initiating steroids after the first day of local ablative therapy and within 14 days after local ablative therapy completion, will be allowed into the study and the use of steroids will be recorded.
Evaluation of Pharmacist Intervention for Individuals With Uncontrolled Type 2 Diabetes

Type 2 diabetes is a chronic disease that can lead to a number of complications if uncontrolled and there is a projected increase of 33% patients living with diabetes over the next 10 years. There can be improvements to modifiable risk factors such as diet and exercise, in addition to medications. Treatment often involves a multidisciplinary approach with a physician, endocrinologist, dietitian, pharmacist and other support health professionals as required. This study will evaluate the effects of the pharmacists (or pharmD interns) intervention, looking at changes to the patients HbA1C, which is a measure of the patients blood glucose control over the previous 3 months as well as the patients understanding and comfort with managing their own diabetes via participant survey.

Recruitment will begin in July 2022, potential participants can self-refer or another healthcare provider may discuss the study and provide contact information to the study team for all interested potential participants. These potential participants would then be screened for eligibility by the pharmacist or PharmD (Doctor of Pharmacy) Intern. The goal is to enroll 60 participants in the study. All participants must provide consent to participate and will be asked to complete a participant survey.

All participants who consented will then be randomized into a control group which will not receive pharmacist intervention during the study period, or the intervention group which will receive pharmacist/PharmD Intern led intervention which includes a medication review, optimizing medication treatment options and frequent follow up and diabetes education. The control group participants will be offered pharmacist intervention following the study period. All participants will be asked to complete a participant survey at the start and end of the study. All participants will also have standard care from their physicians and other healthcare team members as required which would be standard of practice. All participants would also be asked to repeat their blood work at the end of the study period.

Eligibility Criteria:
Inclusion Criteria:

* Patients whose primary care physician is within the Portage Clinic
* Adults (age 18 and older) with type 2 diabetes with HbA1C 10 % or above
* Patients whom have not had previous clinical pharmacist directed intervention
* Agree to participate in the study, including frequent follow up, blood glucose home monitoring as directed and repeat lab work
* Willing to consider medication adjustments as deemed appropriate
* Willing to review and sign the Research Participant Information and Informed Consent Form

Exclusion Criteria:

* Patients less than 18 years of age
* Patients with type 1 diabetes, pre-diabetes or gestational diabetes (or whom are pregnant)
* Patients whom have had recent or ongoing clinical pharmacist directed intervention or intensive health care professional monitoring and guidance
* Patients with HbA1C less than 10%
* Patients whom refuse medication adjustments
* Patients with severe renal impairment or receiving dialysis treatments
The Effects of Metformin on Blood Vessel Structure and Function

The purpose of this study is to evaluate whether the drug Metformin has beneficial effects on the blood vessels of individuals with the Metabolic Syndrome (MeS).

Individuals with the Metabolic Syndrome (MeS) are at increased risk for developing cardiovascular diseases. This increased risk may, in part, be related to abnormalities in the blood vessels. MeS is defined as having 3 or more of the following 5 criteria:

* Abdominal obesity (waist measurement \>39.8 inches in men, \>34.4 inches in women)
* Elevated triglycerides (\>150 mg/dl)
* Low HDL or "good" cholesterol (\<40 mg/dl in men or \<50 mg/dl in women)
* Elevated blood pressure (\>130/85) or treatment for high blood pressure
* Elevated fasting blood sugar (\>100 mg/dl)

Metformin is a medication that is approved by the Food and Drug Administration (FDA) for the treatment of diabetes; however, it can also be safely administered to non-diabetic subjects. We are evaluating whether Metformin reduces the stiffness of blood vessels and improves endothelial function.

This study requires 4 visits to the NIA Clinical Research Center (located on the premises of Harbor Hospital) over a 5-month period. At the initial visit, patients will be given a physical examination with blood and urine tests, and an EKG. They will be randomized into one of two groups; one group will receive Metformin (1700 mg per day), while the other group will receive a placebo. Participants will take the medication for 4 months. Subsequent visits will include additional blood tests, ultrasound and echo exams.

Taking part in this study is entirely voluntary. All testing and medications will be provided at no cost to the participant or their family.

Eligibility Criteria:
Inclusion Criteria:

Participants with the Metabolic Syndrome, which is defined as having 3 or more of the following 5 alterations:

* Abdominal obesity (waist measurement \>39.8 inches in men, \>34.4 inches in women)
* Elevated triglycerides (\>150 mg/dl)
* Low HDL or "good" cholesterol (\<40 mg/dl in men or \<50 mg/dl in women)
* Elevated blood pressure (\>130/85) or treatment for high blood pressure
* Elevated fasting blood sugar (\>100 mg/dl)

Exclusion Criteria:

* Diabetes treated with medication
* Blood pressure \>160/100 mmHg
* Clinical Congestive Heart Failure
* Anemia with hematocrit \<32%
* Asthma or Chronic Obstructive Pulmonary Disease (COPD) requiring daily medication or use of home oxygen therapy
* Major surgery planned within the next six months
* A recent, unexplained weight loss of \>10% of body weight in the past 6 months
* A known allergy or hypersensitivity to Metformin
* History of hepatitis or cirrhosis
* History of kidney disease (defined as serum creatinine \>1.4 mg/dL in men, \>1.3 mg/dL in women)
* Pregnancy or the absence of an effective method of contraception
* Illicit drug or alcohol abuse
* Cancer requiring treatment currently or recently completed treatment in the last 2 months